Literature DB >> 10440198

Management of malignant pericardial effusion resulting from recurrent cancer with local instillation of aclarubicin hydrochloride.

O Kawashima1, T Kurihara, M Kamiyoshihara, S Sakata, S Ishikawa, Y Morishita.   

Abstract

To determine the efficacy of aclarubicin hydrochloride in local control of malignant pericardial effusion, the authors carried out a trial of pericardial drainage with local administration of this agent in five patients, whose effusions had produced cardiac tamponade. All patients were women, and their primary cancers, all initially treated surgically, had arisen in the breast (two patients), or lung (three patients). Mean patient age was 54.2 years (range, 43-62). In four patients, improvement permitted removal of the drainage catheter. Two patients (40%) had a complete remission of the malignant pericardial effusion. The other three patients were difficult to evaluate because nonpericardial metastases limited their survival. All patients, however, showed disappearance of malignant cells from the pericardial sac with no cytopathologically demonstrable recurrence. In our few patients, intrapericardial aclarubicin appeared to be highly effective against malignant pericardial effusion.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440198     DOI: 10.1097/00000421-199908000-00015

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  3 in total

1.  Cardiac tamponade due to metastasis from early gastric cancer.

Authors:  Ichiro Akagi; Masao Miyashita; Masayoshi Hashimoto; Hiroshi Makino; Tsutomu Nomura; Keiichi Ohkawa; Yoshikazu Tsuchiya; Takashi Tajiri
Journal:  Clin J Gastroenterol       Date:  2008-11-28

2.  Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study.

Authors:  Mie Kotake; Hisao Imai; Kyoichi Kaira; Tomomi Fujisawa; Yasuhiro Yanagita; Koichi Minato
Journal:  Cancer Chemother Pharmacol       Date:  2019-06-27       Impact factor: 3.333

3.  A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).

Authors:  H Kunitoh; T Tamura; T Shibata; M Imai; Y Nishiwaki; M Nishio; A Yokoyama; K Watanabe; K Noda; N Saijo
Journal:  Br J Cancer       Date:  2009-01-20       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.